These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 8039839

  • 1. Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment.
    Fischli W, Clozel JP, Breu V, Buchmann S, Mathews S, Stadler H, Vieira E, Wostl W.
    Hypertension; 1994 Aug; 24(2):163-9. PubMed ID: 8039839
    [Abstract] [Full Text] [Related]

  • 2. Ro 42-5892 is a potent orally active renin inhibitor in primates.
    Fischli W, Clozel JP, el Amrani K, Wostl W, Neidhart W, Stadler H, Branca Q.
    Hypertension; 1991 Jul; 18(1):22-31. PubMed ID: 1830563
    [Abstract] [Full Text] [Related]

  • 3. Acute hemodynamic effects of ciprokiren, a novel renin inhibitor, in sodium-depleted dogs.
    Clozel JP, Véniant M, Sprecher U, Fischli W.
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):674-7. PubMed ID: 8569232
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Major role of the renin angiotensin system in the neointima formation after vascular injury in guinea pigs.
    Clozel JP, Hess P, Schietinger K, Breu V, Fischli W, Baumgartner HR.
    Life Sci; 1994 Oct; 54(6):PL87-92. PubMed ID: 8295484
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological properties of YM-21095, a potent and highly specific renin inhibitor.
    Shibasaki M, Asano M, Fukunaga Y, Usui T, Ichihara M, Murakami Y, Nakano K, Fujikura T.
    Am J Hypertens; 1991 Dec; 4(12 Pt 1):932-8. PubMed ID: 1815649
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Acute effects of a pseudo-tetrapeptide as renin inhibitor on blood pressure and renin-angiotensin system of sodium-repleted and sodium-depleted hypertensive patients.
    Denolle T, Luo P, Guyene TT, Cazaubon C, Sissmann J, Corvol P, Ménard J.
    Arzneimittelforschung; 1993 Feb; 43(2A):255-9. PubMed ID: 8498973
    [Abstract] [Full Text] [Related]

  • 11. Effect of an orally active renin inhibitor Cl-992 on blood pressure in normotensive and hypertensive monkeys.
    Ryan MJ, Hicks GW, Batley BL, Rapundalo ST, Patt WC, Taylor DG, Keiser JA.
    J Pharmacol Exp Ther; 1994 Jan; 268(1):372-9. PubMed ID: 8301578
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J, Wuerzner G, Jensen C, Brunner HR.
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [Abstract] [Full Text] [Related]

  • 13. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition.
    Kiowski W, Linder L, Kleinbloesem C, van Brummelen P, Bühler FR.
    Circulation; 1992 Jan; 85(1):1-8. PubMed ID: 1728438
    [Abstract] [Full Text] [Related]

  • 14. Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system.
    Himmelmann A, Bergbrant A, Svensson A, Hansson L, Aurell M.
    Am J Hypertens; 1996 Jun; 9(6):517-22. PubMed ID: 8783774
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.